Transplantation · 1999 · 85 citations · 18 references
Life SciencesImmunologyNephrologyKidney TransplantationTransplant ImmunologyTransplant SurgeryAllograft RejectionAntibody-mediated RejectionDonor-specific AntibodiesGraft RejectionHla MatchingTransplant RejectionDonor-specific Antibody AssessmentFlow Cytometry AntibodiesFlow Cytometry ImmunophenotypingHla Matching In TransplantationHuman Leukocyte Antigen AntibodiesPanel Reactive AntibodiesPanel Reactive Antibody ScreeningRecipient Graft Survival
BACKGROUND: At our transplant center, primary recipients of either a haplo-identical (haplo-ID) living related (LRD) or a cadaveric (CAD) donor renal allograft are transplanted after a negative donor-specific IgG anti-human globulin (AHG) cross-match (XM). Testing included the historically highest panel-reactive antibody and the immediate (0-7 days) pretransplant sera. A positive donor specific IgM-AHG XM has not been a contraindication to transplant. Reports suggest that donor-specific flow cytometry cross-matches (FCXM) may be more clinically informative than the AHG-XM. METHODS: We therefore evaluated the impact of a positive FCXM (IgG or IgM) on the rejection frequency (0-12 months after transplant) and 1-year graft survival for cyclosporine-prednisone-treated primary (haplo-ID and CAD) renal allograft recipients. All transplants were performed after a negative donor-specific IgG AHG-XM regardless of the IgM-AHG XM status. RESULTS: Rejection frequencies (26% vs. 31%, P = NS) and 1-year graft survivals (92% vs. 89%, P = NS) were comparable for haplo-ID LRD FCXM-negative and IgG-FCXM-positive recipients. However, IgM-FCXM-positive LRD recipients experienced significantly fewer rejections (13% vs. 26% P<0.02) and an improved 1-year graft survival (100% vs. 92%, P<0.02) than FCXM-negative LRD recipients. Similar results were observed for primary CAD recipients. Rejection frequencies (40% vs. 44%, P = NS) and 1-year graft survivals (83% vs. 81%, P = NS) were comparable for primary CAD FCXM-negative and IgG-FCXM-positive recipients. Again, IgM-FCXM-positive primary CAD recipients experienced significantly fewer rejections (22% vs. 40%, P<0.02) and improved 1-year graft survivals (89% vs. 83%, P<0.05) than FCXM-negative recipients. CONCLUSION: These data suggest that, after a negative donor-specific IgG-AHG XM, an IgG-positive FCXM is not a contraindication to transplantation. The presence of IgM may be beneficial in reducing the occurrence of rejection episodes and improving graft survivals.
18
THE FLOW CYTOMETRIC CROSSMATCH AND EARLY RENAL TRANSPLANT LOSS
Richard J. Mahoney, Kenneth A. Ault, Shelley R. Given et al. · Transplantation · 1990 · 129 citations
Life Sciences, Nephrology, Surgery +17
THE SIGNIFICANCE OF A POSITIVE FLOW CYTOMETRY CROSSHATCH TEST IN PRIMARY KIDNEY TRANSPLANTATION
K. OCURA, Paul I. Terasaki, Catherine Johnson et al. · Transplantation · 1993 · 128 citations
Medicine, Immunology, Nephrology +15